Gallamini A, Di Raimondo F, La Nasa G, et al. Standard therapies versus novel therapies in Hodgkin lymphoma. Immunol Lett. 2013;155(1-2):56-59. doi: 10.1016/j.imlet.2013.09.011. Epub 2013 Oct 16.
Marri PR, Hodge LS, Maurer MJ, et al. Prognostic significance of pretreatment serum cytokines in classical Hodgkin lymphoma. .Clin Cancer Res. 2013;19(24):6812-6819. doi: 10.1158/1078-0432.CCR-13-1879. Epub 2013 Oct 18.
Klimm B, Goergen H, Fuchs M, et al. Impact of risk factors on outcomes in early-stage Hodgkin's lymphoma: an analysis of international staging definitions. Ann Oncol. 2013;24(12):3070-3076. doi: 10.1093/annonc/mdt413. Epub 2013 Oct 22.
Venkataraman G, Kamran Mirza M, Eichenauer DA, et al. Current status of prognostication in classical Hodgkin lymphoma. Br J Haematol. 2014 Feb 4. doi: 10.1111/bjh.12759. [Epub ahead of print]
ESH International Conference on Lymphomas
Marseille, France, 28–30 October 2012
Expert Rev. Hematol.6(1), 35–37 (2013)

Borchmann P, Eichenauer DA, Engert A. State of the art in the treatment of Hodgkin lymphoma. Nat. Rev. Clin. Oncol.9(8),450–459(2012).
Steidl C, Lee T, Shah SP, et al. Tumor-associated macrophages and survival in classic Hodgkin’s lymphoma. N. Engl. J. Med.362(10),875–885(2010).
Borchmann P, Haverkamp H, Diehl V, et al. Eight cycles of escalated-dose BEACOPP compared with four cycles of escalated-dose BEACOPP followed by four cycles of baseline-dose BEACOPP with or without radiotherapy in patients with advanced-stage Hodgkin’s lymphoma: final analysis of the HD12 trial of the German Hodgkin Study Group. J. Clin. Oncol.29(32),4234–4242(2011).
Chen R, Palmer JM, Thomas SH, et al. Brentuximab vedotin enables successful reduced-intensity allogeneic hematopoietic cell transplantation in patients with relapsed or refractory Hodgkin lymphoma. Blood119(26),6379–6381(2012).
Younes A, Gopal AK, Smith SE, et al. Results of a pivotal Phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin’s lymphoma. J. Clin. Oncol.30(18),2183–2189(2012).